

## 2022 Taoiseach Award Honoree

*John P. Furey*

**Chief Executive Officer, Imvax**



John P. Furey leads Imvax as Chief Executive Officer and also serves on the Board of Directors. Most recently, Mr. Furey was Chief Operating Officer of Spark Therapeutics, Inc., where he led the successful U.S. launch of LUXTURNA™, the first FDA-approved gene therapy for a genetic disease, and contributed to the build-out of Spark as a fully integrated company. Before Spark, Mr. Furey served as Senior Vice President and Head of Global Operations at Baxalta, where he transformed the company's global operations into a first-in-class supply chain network for rare diseases and led the 14,000-employee manufacturing, quality, engineering, and process development organization. Earlier in his career, Mr. Furey initiated the restructuring and ultimate divestiture of Baxter International's vaccines franchise to Pfizer. While at Pfizer, he transformed the China vaccine business into one of the company's fastest-growing units.

Mr. Furey also currently serves on the board of directors of Adaptimmune (NASDAQ: ADAP), a leader in T-cell therapy, and Sensorion, a pioneering clinical-stage biopharmaceutical company developing therapies for the ear. Mr. Furey earned an executive MBA from St Joseph's University, a B.S. with Honors from Trinity College, Dublin, and a Diploma in Environmental Health from the Technological University, Dublin.

